Fairvalue-Calculator Fairvalue-Calculator
EN DE

Taiyen Biotech Co (1737) Fair Value & Analysis

Consumer Defensive · TW · Market cap 6.4B TWD

Price31.95 TWD
Fair Value32.59 TWD
Upside+2.0%
Quality95/100
Evidence: High Range 25.90 TWD – 42.21 TWD

Fair value as of: Jun 24, 2026

Analysis

Taiyen Biotech Co (1737) currently trades at 31.95 TWD, while our model-based Fair Value estimate is 32.59 TWD — implying the stock looks roughly 2.0% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

The Procter & Gamble Company (PG) -26% L'Oréal S.A (LRLCF) -54% Unilever PLC (UNLYF) -22% Colgate-Palmolive Company (CPA) -29% Hindustan Unilever Limited (HINDUNILVR) -68% Reckitt Benckiser Group (RBGLY) +41%

Frequently asked questions

Is Taiyen Biotech Co (1737) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 32.59 TWD versus a price of 31.95 TWD — about +2% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1737?
Our 21-model fair value for Taiyen Biotech Co is 32.59 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 31.95 TWD.
What is the quality score of 1737?
Taiyen Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.